Eiger BioPharmaceuticals, Inc.
EIGR
Kedudukan dalam Saham
#36454
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company... Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and bringing to market targeted therapies for rare and ultra-rare diseases across the United States and internationally. Its primary investigational drug, Lonafarnib, an orally administered small molecule, is currently undergoing Phase III clinical trials for the treatment of hepatitis delta virus (HDV) infection. Other promising candidates in its portfolio include Lambda, which has completed Phase II clinical trials and is designed to target type III interferon receptors; Lonafarnib, also being evaluated for progeria and progeroid laminopathies; and Avexitide, an agent for congenital hyperinsulinism that has also successfully concluded Phase II studies for post-bariatric hypoglycemia. Established in 2008, Eiger BioPharmaceuticals, Inc. maintains its headquarters in Palo Alto, California.
Harga Saham
$1.73
Disegerakkan terakhir: 2025-06-17
Modal Pasaran
$2.55M
Perubahan (1 hari)
-0.29%
Perubahan (1 tahun)
-79.71%
Negara
US
Perdagangan Eiger BioPharmaceuticals, Inc. (EIGR)
Kategori
Healthcare
Pendapatan untuk Eiger BioPharmaceuticals, Inc. (EIGR)
Pendapatan pada Dec 2023 TTM: $-74.96M
Menurut laporan kewangan terkini Eiger BioPharmaceuticals, Inc., pendapatan semasa syarikat ialah $-74.96M. Pada tahun 2022, syarikat memperoleh pendapatan sebanyak $-96.75M, penurunan berbanding pendapatan pada tahun 2021 yang berjumlah $-33.85M. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Eiger BioPharmaceuticals, Inc. dari 2016 hingga 2026
Pendapatan pada akhir setiap tahun
| Tahun | Pendapatan | Ubah |
|---|---|---|
| 2026 (TTM) | $-74.96M | 0.00% |
| 2023 | $-74.96M | -22.53% |
| 2022 | $-96.75M | 185.80% |
| 2021 | $-33.85M | -47.96% |
| 2020 | $-65.05M | -7.40% |
| 2019 | $-70.25M | 34.09% |
| 2018 | $-52.39M | 23.42% |
| 2017 | $-42.45M | -9.85% |
| 2016 | $-47.09M | 0.00% |
Pendapatan untuk syarikat atau pesaing serupa
| Syarikat | Pendapatan | Perbezaan Pendapatan | Negara |
|---|---|---|---|
| $5.27B | -7,137.23% |
US
|
|
| $-3.09B | 4,018.36% |
US
|
|
| $-4.02B | 5,258.00% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -2,702.36% |
NL
|
